Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × selinexor × Myeloid × Clear all

Phase

Phase 1 4 Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 5 Other hematologic neoplasm 2 Myeloid 1 Lymphoid 1 Gynecologic 1

Conditions

Primary Myelofibrosis 1 Myeloproliferative Disorders 1

Interventions

Imatinib Mesylate 27 nilotinib 19 Cytarabine 19 Methotrexate 13 Hydroxyurea 13 Cyclophosphamide 13 Busulfan 13 Peripheral Blood Stem Cell Transplantation 11 Etoposide 11 Whole-Body Irradiation 9 ruxolitinib 8 fludarabine phosphate 8 fludarabine 8 Idarubicin 8 Radiotherapy 7 Mitoxantrone 7 Interferon-alpha 7 Daunorubicin 7 Tacrolimus 6 Mycophenolic Acid 6 bosutinib 5 asciminib 5 Melphalan 5 Cyclosporine 5 Azacitidine 5 luspatercept 4 Thioguanine 4 Dasatinib 4 thymoglobulin 3 peginterferon alfa-2b 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04562389 2025-10-03

SENTRY

Karyopharm Therapeutics Inc

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡